
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Catch up on dermatology news from January 2026, expert insights on dermatologic disease management, and more.
January 2026 has seen a broad range of noteworthy developments within the field of






